Engineered amphibian peptide shows lasting metabolic benefits in mice

A modified version of an amphibian-derived peptide, engineered to persist far longer in the bloodstream, has shown substantial metabolic and liver-protective effects in mice, according to a study published in the Journal of Pharmaceutical Investigation. The construct, named PGLa-ABD-AFF, is built from PGLa-AM1, a short peptide originally found in amphibians, and was redesigned to overcome one of the biggest obstacles in peptide drug development: rapid clearance from the body.

Non-alcoholic fatty liver disease, the condition the researchers set out to address, is a widespread metabolic disorder characterized by fat accumulation in the liver, insulin resistance, and progressive liver injury. Despite a growing global burden, effective pharmacological treatments remain limited, and long-acting peptide-based agents have been proposed as one possible way to fill this therapeutic gap. The new study positioned PGLa-ABD-AFF as a candidate for exactly that role.

The engineering strategy behind the construct involved fusing the PGLa peptide with two additional molecular components. The first is an albumin-binding domain, which allows the molecule to hitch a ride on serum albumin, and the second is an FcRn-targeting affibody, which engages the neonatal Fc receptor recycling pathway. Together, these modifications were designed to extend the molecule’s circulatory half-life, keeping it active for far longer than the original peptide would survive on its own.

Once designed, the fusion protein was expressed, purified, and evaluated for purity and in vitro safety. The researchers report that PGLa-ABD-AFF was successfully produced with high purity and demonstrated a favorable safety profile in laboratory tests.

Biodistribution studies added another layer of detail to the molecule’s behavior in the body. After administration, PGLa-ABD-AFF accumulated predominantly in the liver and kidneys.

The therapeutic evaluation was carried out in vivo, with the researchers assessing a broad set of metabolic and hepatic endpoints. Treatment with PGLa-ABD-AFF significantly improved glucose homeostasis, reduced body weight, and lowered caloric intake in the animals.

Perhaps the most striking finding concerned the liver itself. The treatment markedly attenuated hepatic steatosis, the buildup of fat that defines fatty liver disease. In addition to this direct hepatic benefit, the researchers examined pancreatic islet morphology and found that PGLa-ABD-AFF preserved islet architecture by alleviating the hypertrophy that metabolic stress induces in these insulin-producing structures.

The authors conclude from these findings that PGLa-ABD-AFF is a potent long-acting peptide therapeutic with beneficial metabolic and hepatoprotective effects. They argue that the prolonged systemic exposure, combined with efficacy across multiple organs, supports its potential as a promising candidate for treating obesity-associated metabolic dysfunction and hepatic steatosis.

As with any preclinical study, the results come from mouse models and in vitro testing, and translating a 47-hour half-life and multi-organ benefits into human therapy would require the full sequence of clinical development steps.

Subject of Research: Engineering of the long-acting peptide PGLa-ABD-AFF and its preclinical evaluation against metabolic and liver disorders

Article Title: Long-acting PGLa-AM1: genetic engineering and in vivo evaluation of its efficacy against metabolic disorders

Article References: Amatya, R., Joseph, A., Roh, G. S., Hyun, J. Y., Benmokadem, Y., Min, K. A., & Shin, M. C. (2026). Long-acting PGLa-AM1: genetic engineering and in vivo evaluation of its efficacy against metabolic disorders. Journal of Pharmaceutical Investigation. https://doi.org/10.1007/s40005-026-00832-3

Image Credits: AI Generated

DOI: 10.1007/s40005-026-00832-3

Keywords: PGLa-AM1, PGLa-ABD-AFF, peptide therapeutics, albumin-binding domain, FcRn-targeting affibody, non-alcoholic fatty liver disease, hepatic steatosis, glucose homeostasis, pharmacokinetics, biodistribution, pancreatic islets, obesity